Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on September 22, 2005, covering events occurring on September 16, 2005. The filing details significant executive leadership changes, including a promotion to Executive Vice President and President, Worldwide Pharmaceuticals, and the planned departure of the Executive Vice President and President, Americas.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data presented is limited to specific executive compensation and severance packages:
- Lamberto Andreotti (Promoted): Annual base salary of $975,000; target total cash compensation of $2,047,500; restricted stock award of 125,000 shares.
- Elliott Sigal (Bonus Increase): Annual base salary of $695,250; target total cash compensation of $1,320,975; special restricted stock award of 50,000 shares.
- Donald J. Hayden, Jr. (Separation): Severance pay totaling $746,598 (56 weeks of base salary); pro-rata vesting of restricted stock and accelerated vesting of stock options held at least one year; eligibility for pro-rata payments from 2004-2006 and 2005-2007 performance cycles.
Material Changes Versus Prior Period
The filing reports material changes in executive leadership structure effective September 20, 2005:
- Appointment: Lamberto Andreotti was promoted from Senior Vice President and President, International, to Executive Vice President and President, Worldwide Pharmaceuticals.
- Departure: Donald J. Hayden, Jr. agreed to terminate employment effective March 2, 2006. He assumed a transitional role effective September 20, 2005, to ensure an orderly transition of responsibilities.
- Compensation Adjustments: Target bonus increases were approved for Dr. Elliott Sigal, Chief Scientific Officer.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or general risk factors. The primary contingency noted is the separation agreement with Donald J. Hayden, Jr., which includes a general release and customary non-solicitation provisions. The company intends to manage the transition of Mr. Hayden's responsibilities through March 2, 2006.
Investor Verification Checklist
- Verify the effective date of Lamberto Andreotti's new role (September 20, 2005) and the scope of his new responsibilities.
- Confirm the terms of Donald J. Hayden, Jr.'s separation agreement, specifically the March 2, 2006 termination date and the calculation of his severance benefits.
- Review the vesting schedules for the restricted stock awards granted to Mr. Andreotti (1/3 per year in years 3, 4, and 5) and Dr. Sigal.
- Check subsequent filings for any changes to the transition plan or additional executive departures.